DTG/3TC与BIC/FTC/TAF在极高病毒载量HIV感染者中的疗效比较
单中心回顾性队列研究纳入40例基线HIV-RNA≥500 000 copies/mL且CD4+≥200/mm3的初治HIV-1感染者,比较DTG/3TC与BIC/FTC/TAF第48周病毒学抑制率。两组的抑制率分别为90.5%和94.7%(log-rank P=0.73),免疫恢复与安全性无显著差异。
要点
- 极高病毒载量初治患者中,DTG/3TC与BIC/FTC/TAF第48周病毒学抑制率相似。
- 两组CD4+计数增益、体重、血脂及肌酐变化均无显著差异。
- 未观察到耐药相关病毒学失败或治疗中断。
核心结论
- 在HIV-RNA≥500 000 copies/mL且CD4+≥200/mm3的初治成人中,DTG/3TC与BIC/FTC/TAF第48周疗效和安全性相当。
研究设计与样本
- 单中心回顾性队列研究,纳入2019-2024年启动DTG/3TC或BIC/FTC/TAF的初治HIV-1感染者,共40例。
主要发现
- 第48周病毒学抑制率(ITT,M=F)DTG/3TC组为90.5%(19/21),BIC/FTC/TAF组为94.7%(18/19),log-rank P=0.73。
- 中位CD4+增益分别为385 vs 243 cells/mm3(P=0.30)。
- 两组病毒衰减动力学相似,未观察到耐药相关病毒学失败或治疗中断。
- 体重增加、血脂谱和肌酐水平无显著差异。
临床怎么用
- 对于基线极高病毒载量且CD4+≥200/mm3的初治HIV感染者,可考虑使用DTG/3TC或BIC/FTC/TAF。
局限性
- 样本量小(40例)且为单中心回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the effectiveness of dolutegravir/lamivudine (DTG/3TC) versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) at Week 48 in treatment-naive adults with high baseline viral loads (≥500 000 copies/mL) and CD4+ cell count ≥200/mm3 and to assess immune recovery and safety. METHODS: We conducted a single-centre retrospective cohort study including all ART-naive people with HIV-1 (PWH) and HIV-RNA ≥500 000 copies/mL and CD4+ ≥200 cells/mm3 who initiated DTG/3TC or BIC/FTC/TAF during 2019-2024. Effectiveness was assessed as the proportion of participants achieving HIV-1 RNA <50 copies/mL at Week 48 [intention-to-treat, missing = failure (ITT, M = F)]. Immune recovery, metabolic and renal safety were evaluated through changes in CD4+ count, weight, lipid profile and creatinine. Time-to-virologic suppression was analysed using Kaplan-Meier curves and log-rank testing. Safety profile and immune recovery were conducted using Mann-Whitney U test. RESULTS: A total of 40 patients (52.5% on DTG/3TC, 47.5% on BIC/FTC/TAF) were included, with a high prevalence of primary HIV infection (PHI) (76.2% and 84.2%, respectively). No baseline differences were observed between groups. At 48 weeks, virologic suppression rates were 90.5% (19/21) in the DTG/3TC group and 94.7% (18/19) in the BIC/FTC/TAF group (log-rank P = 0.73). Viral decay kinetics were similar between groups. No virologic failures with resistance or treatment discontinuations were observed. Median CD4+ gains were comparable between groups (385 vs 243 cells/mm3; P = 0.30). No significant differences in weight gain, lipid profile, or creatinine levels were observed. CONCLUSIONS: In ART-naive PWH with HIV-RNA ≥500 000 cp/mL and CD4+ ≥200/mm3, including those with PHI, DTG/3TC and BIC/FTC/TAF showed similar effectiveness and comparable safety profiles at Week 48.
引用
- Martin-Torres J, Navarro-Soler R, Iglesias-Franco J, et al. Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL). J Antimicrob Chemother. 2026. PMID: 42627147. doi:10.1093/jac/dkag285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。